Literature DB >> 12095927

Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma.

L Giannitrapani1, M Cervello, M Soresi, M Notarbartolo, M La Rosa, L Virruso, N D'Alessandro, G Montalto.   

Abstract

Interleukin-6 plays a central role in regulating the immune system, hematopoiesis, and acute phase reaction. It interacts with a receptor complex consisting of a specific ligand-binding protein (IL-6R, gp80) and a signal transduction protein (gp130). In this report, serum levels of IL-6 and a soluble form of the interleukin-6 receptor (sIL-6R) were evaluated in patients with hepatocellular carcinoma. The correlation between IL-6 and sIL-6R values, the stage of hepatocellular carcinoma, and main liver function tests was also studied.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12095927     DOI： 10.1111/j.1749-6632.2002.tb04093.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


  20 in total

1.  A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.

Authors:  Heidi V Russell; Susan G Groshen; Tasnim Ara; Yves A DeClerck; Randy Hawkins; Hollie A Jackson; Heike E Daldrup-Link; Araz Marachelian; Andrej Skerjanec; Julie R Park; Howard Katzenstein; Katherine K Matthay; Susan M Blaney; Judith G Villablanca
Journal:  Pediatr Blood Cancer       Date:  2010-11-12       Impact factor: 3.167

2.  Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma.

Authors:  Maurizio Soresi; Lydia Giannitrapani; Fabio D'Antona; Ada-Maria Florena; Emanuele La Spada; Angela Terranova; Melchiorre Cervello; Natale D'Alessandro; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

3.  Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma.

Authors:  Andrea M Griesinger; Rebecca J Josephson; Andrew M Donson; Jean M Mulcahy Levy; Vladimir Amani; Diane K Birks; Lindsey M Hoffman; Steffanie L Furtek; Phillip Reigan; Michael H Handler; Rajeev Vibhakar; Nicholas K Foreman
Journal:  Cancer Immunol Res       Date:  2015-05-12       Impact factor: 11.151

4.  Cytokine profile in Egyptian hepatitis C virus genotype-4 in relation to liver disease progression.

Authors:  Abdel-Rahman N Zekri; Mohammed S El-Din Ashour; Ahmed Hassan; Hanaa M Alam El-Din; Amal M R El-Shehaby; Maha A Abu-Shady
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

5.  Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25).

Authors:  Roniel Cabrera; Miguel Ararat; Mengde Cao; Yiling Xu; Clive Wasserfall; Mark A Atkinson; Chen Liu; David R Nelson
Journal:  Dig Dis Sci       Date:  2010-02       Impact factor: 3.199

Review 6.  Multifactorial nature of hepatocellular carcinoma drug resistance: could plant polyphenols be helpful?

Authors:  Natale D'Alessandro; Paola Poma; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2007-04-14       Impact factor: 5.742

Review 7.  Immunology of hepatocellular carcinoma.

Authors:  Meenakshi Sachdeva; Yogesh K Chawla; Sunil K Arora
Journal:  World J Hepatol       Date:  2015-08-18

8.  Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB.

Authors:  Jinbo Yang; Xudong Liao; Mukesh K Agarwal; Laura Barnes; Philip E Auron; George R Stark
Journal:  Genes Dev       Date:  2007-05-17       Impact factor: 11.361

9.  Lentiviral vector-mediated down-regulation of IL-17A receptor in hepatic stellate cells results in decreased secretion of IL-6.

Authors:  Sheng-Chu Zhang; Yi-Hu Zheng; Pan-Pan Yu; Tan Hooi Min; Fu-Xiang Yu; Chao Ye; Yuan-Kang Xie; Qi-Yu Zhang
Journal:  World J Gastroenterol       Date:  2012-07-28       Impact factor: 5.742

Review 10.  New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology.

Authors:  Maria D Giraldez; David Carneros; Christoph Garbers; Stefan Rose-John; Matilde Bustos
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-07-01       Impact factor: 46.802
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.